Atea Pharmaceuticals, Inc. reported $351M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $351M (to Q4 2021). Net income: −$165M, trailing twelve months to Q2 2026. EPS: −$2.08, trailing twelve months to Q2 2026.

AVIRAtea Pharmaceuticals, Inc.

Healthcare

$5.15+73% 1Y

$5.15

$2.9652 weeks$6.15

AVIR as reported

Atea Pharmaceuticals, Inc. reported $351M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$351M

Revenue, trailing twelve months · to Q4 2021 · every figure below is as filed, with no scoring applied

Net income: −$165M
Net income · +21% year on year · trailing twelve months to Q2 2026
EPS: −$2.08
EPS · +29% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AVIR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$351M	n/a	Q4 2021 · 18 quarters behind
Net income	−$165M	+21%	Q2 2026
EPS	−$2.08	+29%	Q2 2026
Operating margin	14%	n/a	Q4 2021 · 18 quarters behind
Net margin	6.0%	n/a	Q4 2021 · 18 quarters behind
ROE	−64%	n/a	Q2 2026
ROA	−57%	n/a	Q2 2026
Free cash flow	−$123M	n/a	Q4 2022 · 14 quarters behind
P/E	29.4	n/a	Q3 2022 · 15 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.